Nilanjana Basu is a correspondent specializing in local business news in India. She writes for Seeking Alpha and her work has also appeared in exchange4media. Nilanjana covers a wide range of topics including corporate appointments, financial announcements, and market updates.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Nilanjana's focus is on local Indian coverage of financial results, stock market movements, and company news. She often cites data and press releases but also includes expert commentary. Given the heavy emphasis on financial results and stock market movements, pitches related to in-depth analysis of corporate performance within the Indian context would likely resonate with her. Moreover, she may be receptive to interviews or insights from experts who can provide valuable perspectives on sales & marketing strategies or industry partnerships within India.
It's essential for sources reaching out to Nilanjana Basu to have a strong understanding of the Indian business landscape and its specific nuances when it comes to financial reporting, as this aligns with her primary areas of interest.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Nilanjana Basu
Chemours Company announces pricing of $600M 8.000% senior notes due 2033.
By: Nilanjana Basu
Faraday Future announces strategic licensing collaboration with Grow Fandor, showcasing potential economic benefits and exclusive licensing rights.
By: Nilanjana Basu
Bluejay Diagnostics (BJDX) announces a reverse stock split at a ratio of 1-for-50 effective November 18, 2024, trading on Nasdaq Capital Market.
Icahn Enterprises L.P. (IEP) has announced the pricing of $500M in Senior Secured Notes due 2029 in a private placement.
By: Nilanjana Basu
REGENXBIO (RGNX) stock rises 4% as the company prepares to discuss new clinical data for their Duchenne muscular dystrophy gene therapy.
By: Nilanjana Basu
Moleculin Biotech accelerates clinical trial data readout for Annamycin in AML patients, remains on track for Phase 3 trial in Q1 2025.
By: Nilanjana Basu
EchoStar Corporation (SATS) files prospectus for offer and sale of up to 11.5M shares of Class A common stock.
By: Nilanjana Basu
AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.
Milestone Scientific CEO Arjan Haverhals to retire on December 31, 2024, with Neal Goldman appointed as Interim CEO.
Associated Banc-Corp (ASB) announces a proposed public offering of 11.5M shares of its common stock, with an option for additional shares.
(833) 317-6278 
